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The muscarinic agonist oxotremorine produced a linear dose-dependent increase in membrane fluidity of 
intact and viable human lymphocytes in vitro. This effect proved to be receptor-mediated because preincu- 
bation with 10m5 M atropine shifted the dose-response curve one order of magnitude rightward. Pirenzepine 
preincubation did not affect membrane fluidity variation. A cGMP increase was also found after oxotremor- 
ine treatment. The results are discussed in terms of possible modulation of guanyl cyclase and adenyl cyclase 
through membrane fluidity variations. 
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1. INTRODUCTION 
Membrane fluidity changes consequent to the 
association of a membrane receptor with agonists 
or antagonists have been reported for a variety of 
compounds in a number of tissues [1,2]. These 
membrane changes were observed concomitantly 
with the stimulation of certain biochemical reac- 
tions within the cell including protein phosphoryla- 
tion, Ca*+ mobilization, methyltransferase induc- 
tion and extracellular ion influx [3-61. Peripheral 
blood lymphocytes respond to muscarinic agonists 
with increased cGMP levels. Muscarinic agonists 
like carbamylcholine and acetylcholine alter lym- 
phocyte function causing changes in motility and 
immunological activity. This effect was stopped by 
drugs eliciting CAMP synthesis [7]. This fact sug- 
gests an involvement of the muscarinic M2 
receptor. 
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The muscarinic cholinergic receptor has been 
demonstrated to be present on the human lym- 
phocyte surface [8]. The purpose of our work was 
to determine whether the muscarinic agonist ox- 
otremorine modified membrane fluidity in intact 
and viable human lymphocytes. Such an alteration 
could permit modulation of adenyl cyclase and 
guanyl cyclase activities, since they are membrane- 
associated enzymes whose activity is strongly 
dependent on membrane physical parameters. 
Knowledge of such molecular mechanisms would 
lend some support to the use of human lym- 
phocytes as a model for studies on the cholinergic 
muscarinic system. 
2. MATERIALS AND METHODS 
Human lymphocytes were obtained from blood 
serum of healthy male volunteers by the method of 
Boyum [9]. Their purity was always more than 
90%. Membrane microviscosity was determined 
according to Shinitzky and Barenholz [IO] using 
1,3,5diphenylhexatriene (DPH) as a probe. 
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The fluorescence polarization value was deter- 
mined on an Elscint MV-1 microviscosimeter 
(Haifa, Israel). Lymphocytes were incubated with 
2 x 10m6 M DPH in PBS (phosphate-buffered 
saline) at 37°C for 30 min. 
The in vitro changes of lymphocyte 
microviscosity were determined by adding ox- 
otremorine dissolved in PBS at the appropriate 
concentration to 3 ml DPH-labelled lymphocytes 
(0.1-0.25 mg protein/ml) to obtain a drug concen- 
tration of lo-‘-3 x 10e4 M. DPH-labelled lym- 
phocyte samples were preincubated with atropine 
(10e5 M) or pirenzepine at the same concentration 
at 37°C before the addition of oxotremorine. 
The membrane-fluidizing effect was measured 
as follows: the P value was determined before drug 
addition and every 2 min until no further 
microviscosity change was observed. The data for 
all the determinations refer to this peak time. 
The possible spectral interaction of DPH with 
the drugs was verified by checking there was no in- 
terfering absorbance at the DPH emission 
wavelength. 
Proteins were determined according to Lowry et 
al. [l 11. Lymphocyte cGMP was determined ac- 
cording to Study et al. [12]. Atropine sulfate was 
obtained from Sigma, oxotremorine sesquifuma- 
rate from Aldrich, pirenzepine-HCl from Dr Karl 
Thomae, Biberach (FRG), carbamylcholine from 
Janssen Pharmaceuticals and nicotine from Sigma. 
3. RESULTS 
Fig.1 shows the time course of changes in mem- 
brane microviscosity after addition of 10e4 M ox- 
otremorine. The maximum decrease was attained 
at 20 min, and remained stable for at least another 
20 min. This figure also shows for comparison the 
effect of 10e5 M atropine alone and prior to in- 
cubation with oxotremorine. Neither treatment 
had any significant effect on membrane 
microviscosity. 
Fig.2 reports the data after addition of ox- 
otremorine at various doses (10W5-3 x lop4 M) to 
untreated lymphocytes or to cells preincubated 
with lo-’ M atropine. The data are expressed as 
the ratio of the membrane microviscosity 20 min 
after addition of oxotremorine (i.e_. SD) and the 
basal value (i.e. 70) vs the logarithm of the drug 
concentration. The fluidizing effect of ox- 
Fig.1. Effects of 10e4 M oxotremorine (A), 10e5 M 
atropine (0) and 10e4 M oxotremorine after 
preincubation with 10m5 M a&opine (0). The abscissa 
shows the time (in min) after the addition of 
oxotremorine to the cuvette. Atropine was added 15 min 
before oxotremorine. The ordinate shows the 
microviscosity (in P). 
Fig.2. Dose-response curve of oxotremorine-induced 
fluidity change in intact and viable human lymphocytes 
(0) and the effect of atropine (0). The abscissa shows 
the concentration in logarithmic units. The ordinate 
shows the relative microviscosity measured 20 min (peak 
time) after addition of oxotremorine. The results are 
expressed as the mean f SE of 4 separate experiments. 
In the experiments with a&opine, lo-’ M atropine was 
preincubated with lymphocytes for 15 min at 37°C 
before oxotremorine addition. 
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Fig.3. Dose-response curve of oxotremorine after 
preincubation with 10e5 M pirenzepine. The abscissa 
shows the concentration used in logarithmic units. The 
ordinate shows the relative microviscosity measured as 
in fig.2. Pirenzepine was preincubated with lymphocytes 
for 15 min at 37°C. 
otremorine was linear with concentrations in the 
range 10e5- 3 x low4 M. Preincubation with 
10M5 M atropine caused a powerful rightward shift 
of the dose-response curve of about one order of 
Table 2 
Effect of carbamylcholine and nicotine on membrane 
microviscosity of human lymphocytes 
Drug Dose Microviscosity 
(M) (P) 
None _ 1.957 f 0.006 
Carbamylcholine 1o-4 1.794 t- 0.007a 
Nicotine 1o-4 1.915 + 0.012 
a p < 0.01 vs controls 
Results are the mean + SE of 4 different determinations 
magnitude. Atropine alone did not significantly 
alter lymphocyte membrane microviscosity. 
Fig.3 shows membrane microviscosity variations 
following the treatment with oxotremorine in the 
same range of doses after the preincubation with 
10m5 M pirenzepine. No variation vs oxotremo- 
rine-induced membrane microviscosity changes 
can be observed. Pirenzepine was absolutely inac- 
tive per se. 
Table 1 shows cGMP levels in lymphocytes after 
20 min incubation with lo-’ M atropine, 10m4 M 
oxotremorine and a combination of both. Ox- 
otremorine caused a significant (2-fold) increase in 
cGMP. Atropine alone did not significantly alter 
cGMP content and completely reversed the action 
of oxotremorine. The table also reports the mem- 
brane fluidity values (expressed in P) obtained in 
parallel experiments. Table 2 shows for com- 
parison the effects on membrane fluidity of car- 
bamylcholine and nicotine. The effect of car- 
Table 1 
Effect of atropine and oxotremorine on cyclic GMP content and 
membrane fluidity of human lymphocytes 
Drug Dose Cyclic GMP Microviscosity 
W) (pmol/g protein) (P) 
None - 0.121 + 0.004 1.966 -t 0.020 
Atropine 10-5 0.130 k 0.029 1.932 f 0.019 
Oxotremorine 1o-4 0.219 * 0.020a 1.838 + O.OIOa 
Atropine + 10-5 
oxotremorine 1o-4 0.166 ? 0.052 1.915 * 0.010 
ap < 0.01 vs controls 
Each value is the mean + SE of 4 different determinations 
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bamylcholine is somewhat stronger than that of authors [l&19] report a concomitant variation in 
oxotremorine, whereas nicotine is inactive. CAMP and cGMP levels in various tissues. 
4. DISCUSSION 
This paper reports for the first time that mem- 
brane microviscosity can be modified by exposure 
to oxotremorine, a muscarinic agonist. To verify 
this point we made similar experiments using 
another muscarinic agonist, i.e. carbamylcholine. 
The microviscosity modification induced by this 
compound was comparable to that observed with 
oxotremorine in the same concentration range 
(table 2). 
Since adenyl cyclase and guanyl cyclase activities 
are strongly dependent on membrane physical 
parameters [20,21] they could be at least partially 
regulated by membrane fluidity variations. 
Moreover, the long-lasting effect on membrane 
fluidity induced by oxotremorine could be explain- 
ed in terms of long-range effects induced by oc- 
cupancy of cholinergic sites by ligands [22]. 
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